title: Is exclusive Skp2 targeting always beneficial in cancer therapy?
authors.forename: Marilena
authors.initials: M
authors.lastname: Koutsami
authors.forename: Georgia
authors.initials: G
authors.lastname: Velimezi
authors.forename: Athanassios
authors.initials: A
authors.lastname: Kotsinas
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Evangelou
authors.forename: Athanassios G
authors.initials: AG
authors.lastname: Papavassiliou
authors.forename: Christos
authors.initials: C
authors.lastname: Kittas
authors.forename: Vassilis G
authors.initials: VG
authors.lastname: Gorgoulis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000502:physiology; D016503:Drug Delivery Systems; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009154:Mutation / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D034741:RNA, Small Interfering / Q000627:therapeutic use; D044786:S-Phase Kinase-Associated Proteins / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering; D044786:S-Phase Kinase-Associated Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27